When compared to conventional imaging, prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) has higher detection rates and greater diagnostic accuracy for patients with initial high risk, biochemically recurrent or persistent prostate cancer, and mCRPC (6–9). The gene discussed is FOLH1; the disease is Familial prostate cancer.